M itochondrial metabolism is a source of energy and metabolic intermediates that serve various roles in processes including redox homeostasis, anabolism and epigenetics 1 . There is an emerging association between upregulated mitochondrial metabolism and cancer pathogenesis and progression, but the molecular mechanisms underlying this association remain unknown 1-10 . PDC is a gatekeeper multiprotein complex that catalyzes the conversion of pyruvate to acetyl coenzyme A (acetyl CoA), thereby regulating mitochondrial activity. This complex includes a major component, PDHA1, that can be dephosphorylated by the pyruvate dehydrogenase phosphatases (PDPs) Pdp1 and Pdp2 and phosphorylated by the pyruvate dehydrogenase kinases (Pdks) [11] [12] [13] . Whereas dephosphorylation of PDHA1 activates PDC, phosphorylation blocks its activity.
. b, Top, PDC activity measurement in wild-type, Pdha1 pc-/Y , Pten pc−/− and Pten pc−/− ; Pdha1 pc-/Y prostates and tumors (n = 3 independent prostate samples). Bottom, quantification of the indicated proteins normalized to wild-type levels in the prostate tumors in a (n = 3 independent prostate samples). c, Comparison of anterior prostate lobe volumes (mm 3 , two independent lobes per animal presented) from wild-type, Pdha1 pc-/Y , Pten pc−/− and Pten pc−/− ; Pdha1 pc-/Y prostates and tumors from male mice of the indicated ages (n, number of mice). Inset, representative images of anterior prostate lobes. d, Representative micrographs in histopathological analysis (hematoxylin-eosin (H&E) staining and indicated proteins) of anterior prostates in Pdha1 pc-/Y , Pten pc−/− and Pten pc−/− ; Pdha1 pc-/Y prostate tissues from 12-week-old male mice (n = 3). Scale bar, 50 μ m; insets are shown at higher magnification. Data for all the genotypes and images at lower magnification are shown in Supplementary Fig. 1c . e,f, Quantification of the percentage of Ki-67-positive cells (e) and invasive prostate glands (f) in prostates from mice of the indicated genotypes and ages (n, number of mice). g, Relative cell-number quantification by crystal violet staining in the indicated prostate cancer cell lines infected with shPDHA1 or scrambled control. Data are normalized to shRNA control. Inset, PDHA1 inhibition, validated by western blot analysis using two different shPDHA1 constructs. Uncropped images are in Supplementary Fig. 12 (n = 3 independent cell cultures). OD, optical density. h, Spheroid formation assays in LNCaP, 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-shPDHA1 or scrambled control (n = 3 independent cell cultures). Scale bar, 50 µ m. i,j, Quantification of spheroid diameter (i) and spheroid number per 500 cells (j) in LNCaP, 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-shPDHA1 or scrambled Tripz-shRNA control (n = 3 independent cell cultures). k,l, Evaluation of tumor formation in xenotransplantation experiments of 22Rv1 (k) and PC3 (l) cells infected with the indicated shPDHA1 or scrambled-shRNA control. Inset, western blot validation of knockdown of PDHA1 in 22Rv1 and PC3 xenograft tumors. Uncropped images are in Supplementary Fig. 12 (n = 6 animals; 12 independent tumor samples). Error bars, s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. P values were determined by ANOVA with Bonferroni correction, unless otherwise noted. 
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Srebf2 Sqle Acly Acss1 Acss2 Cpt1a Cpt2 Fat/CD36 than that in normal prostates ( Fig. 1a ,b, Supplementary Fig. 1b and uncropped blots in Supplementary Fig. 12 ). Inactivation of Pdha1 in Pten pc−/− tumors abrogated PDC activity and induced a strong growth inhibition in the prostate glands of mice of different ages (Fig. 1c ). This effect was associated with a strong decrease in cell proliferation, as shown by decreases in Ki-67 staining and the number of glands affected by invasive prostate cancer ( Fig. 1d-f and Supplementary Fig. 1c ). The strong arrest in proliferation in Pten pc−/− ; Pdha1 pc-/Y tumors and Pten −/− ; Pdha1 -/Y mouse embryonic fibroblasts (MEFs) occurred independently of senescence 19 and apoptosis, both of which occurred to a lesser extent than that in controls ( Supplementary Fig. 1d -i). Notably, Pdha1 inactivation induced growth arrest exclusively in Pten −/− MEFs, without altering the growth of wild-type MEFs ( Supplementary Fig. 1g ). Moreover, Pdha1 deletion in Pten-null tumors and MEFs did not affect the levels of phospho-Akt at Ser473 and the total amount of mitochondria, as indicated by the protein levels of voltage-dependent anion channel 1 (Vdac1) 5 ( Fig. 1a , Supplementary Fig. 1j and uncropped blots in Supplementary Fig. 13 ).
Next, we assessed the status of both PDHA1 and PDP1 in human prostate cancers. Bioinformatic analysis showed that both PDHA1 and PDP1 are frequently amplified at the gene level and overexpressed in human prostate tumors. Interestingly, PDP1 was found to be amplified (3/3 available datasets) and overexpressed (9/11 datasets) in primary prostate tumors compared with normal prostate tissues, whereas PDHA1 was amplified (2/3 datasets) and overexpressed (7/13 datasets) ( Supplementary Fig. 2a -e) in metastatic tumors compared with primary tumors. We also stained for PDHA1, phospho-PDHA1 and PDP1 on a tissue microarray (TMA) consisting of 128 prostate carcinoma and normal prostate samples. Immunohistochemistry analyses showed that both PDHA1 and PDP1 were frequently overexpressed in human prostate tumors, and their expression was higher in tumors with high Gleason scores ( Supplementary Fig. 3a-c) . In contrast, phospho-PDHA1 staining was high in only a small fraction of cases, which had low Gleason scores ( Supplementary Fig. 3a,d ). Interestingly, most cases with high PDP1 or PDHA1 staining were negative for phospho-PDHA1 ( Supplementary Fig. 3e ). Three out of four prostate cancer cell lines exhibited higher PDC activity than did nontransformed PNT2C2 prostate cells ( Supplementary Fig. 3f ). This result was associated with elevated protein levels of both PDHA1 and PDP1 and enhanced mitochondrial oxygen consumption dependent on both glucose and glutamine utilization ( Supplementary Fig. 3f -i and uncropped blots in Supplementary Fig. 14) . Together, these data demonstrated that in prostate tumors and in cancer cell lines, PDC is active.
We next inactivated PDHA1 in prostate cancer cells by using different PDHA1 short hairpin RNAs (shRNAs). In agreement with the results from the mouse model, we found that PDC inactivation resulted in an apoptosis-independent inhibition of cellular proliferation ( Fig. 1g , Supplementary Fig. 3j ,k and uncropped blots in Supplementary Fig. 12 ). We also detected lower mitochondrial respiration in cells infected with PDHA1 shRNA (shPDHA1) than in control cells ( Supplementary Fig. 3l ). The sphere-forming ability in LNCaP, 22Rv1 and PC3 cells was also impaired after PDHA1 inactivation ( Fig. 1h -j, Supplementary Fig. 3m and uncropped blots in Supplementary Fig. 14) . 22Rv1 and PC3 prostate cancer cells infected with shPDHA1 also formed smaller tumors in vivo than did controls (Fig. 1k ,l and uncropped blots in Supplementary Fig. 12 ).
Pdha1 inactivation decreases mitochondrial intermediates. Next, we performed metabolomic analysis in wild-type prostates, Pdha1 pc-/Y prostates, Pten pc−/− prostates and Pten pc−/− ; Pdha1 pc-/Y prostates. Pten pc−/− tumors showed signs of upregulation of the tricarboxylic acid (TCA) cycle, as measured by elevated levels of citrate, α -ketoglutarate, acetyl CoA, ATP production and nicotinamide adenine dinucleotide (NADH) ( Supplementary Fig. 4a-d , Supplementary   Table 4 and Supplementary Note). Elevated extracellular lactate levels in Pten-null MEFs also suggested greater glycolytic flux in those cells than in controls ( Supplementary Fig. 4e and Supplementary Note). Pdha1 inactivation in Pten-null tumors and MEFs resulted in lower levels of TCA-cycle intermediates such as citrate and α -ketoglutarate and affected the NADH/NAD + ratio and ATP and acetyl CoA levels ( Supplementary Fig. 4a -f, Supplementary Table 4 and Supplementary Note). However, glycolysis and lactate production were not consistently affected ( Supplementary Fig. 4a,e ), in agreement with previous findings in different models [20] [21] [22] . Of note, the oxaloacetate levels were significantly higher in double-mutant mice, in line with a block in the cycle due to loss of acetyl CoA production downstream of PDC ( Supplementary Fig. 4a,d and Supplementary  Table 4 ). To determine whether Pdha1 inactivation induced changes in central carbon metabolism, we measured stationary flux 5, 20 through the TCA cycle in prostate epithelial cells derived from transgenic mice of different genotypes, by using 13 C stable-isotopelabeled glucose, glutamine and palmitate. This analysis showed higher glucose and glutamine incorporation into citrate, fumarate and malate in Pten pc−/− cells than in normal prostate epithelial cells. The glucose incorporation into citrate in Pten pc−/− ; Pdha1 pc-/Y tumor cells, was lower (~70%) than that in Pten pc−/− cells. Importantly, PDC inactivation led to compensatory oxidative glutaminolysis and to the production of acetyl CoA from fatty acid beta-oxidation for the reactivation of the TCA (as reflected in a 30% increase in citrate labeling from palmitate). However, this compensation was not able to overcome the decreased citrate synthesis ( Supplementary  Fig. 4a and Supplementary Table 4 ). Unexpectedly, glutaminolysis restored the oxidative reactions after α -ketoglutarate to fumarate and malate until aspartate synthesis in TCA cycle. However, the glutamine carbon pool was blocked from the reactions for citrate production, probably because of the lower expression of Idh1 in Pten pc−/− ; Pdha1 pc-/Y than in Pten pc−/− tumor cells ( Supplementary  Fig. 5d ,g and Supplementary Tables 5-7) . Finally, the pyruvate carboxylase activity did not change in response to PDHA1 loss, because the M + 3 (isotopomer species with three labeled carbons) aspartate was not higher in Pten pc−/− ; Pdha1 pc-/Y than in Pten pc−/− tumor cells ( Supplementary Fig. 4g and Supplementary Table 5 ). Together, these data demonstrated that PDC inactivation decreases the production of TCA intermediates and energetic yield in prostate tumors.
Pdha1 knockdown induces tumor suppression by abrogating lipogenesis. Pdha1 has long been defined as a mitochondrialmetabolism regulator. However, recent evidence has demonstrated that PDC controls the nuclear pool of acetyl CoA, thereby promoting histone acetylation and regulating gene expression 23, 24 . In line with this evidence, we detected strong nuclear localization of PDHA1 in Pten pc−/− tumors and PDC activity in both the cytosol and nucleus in these tumor cells ( Fig. 1d , Supplementary Figs. 1c and 5a,b and uncropped blots in Supplementary Fig. 14) . We also detected Pdha1, Dlat and Dld in the nuclear fractions of Pten pc−/− tumor cells ( Supplementary Fig. 5c and uncropped blots in Supplementary Fig. 14) . Transcriptomics followed by gene set enrichment analysis (GSEA) in Pten pc−/− and Pten pc−/− ; Pdha1 pc-/Y tumors demonstrated that fatty acid synthesis, cholesterol biogenesis and expression of genes controlled by the SREBF [25] [26] [27] [28] were the most downregulated pathways in Pten pc−/− ; Pdha1 pc-/Y tumors ( Fig. 2a ). Inactivation of Pdha1 in Pten pc−/− tumors and shPDHA1 human prostate cancer cells decreased the levels of acetylated histone H3 Lys9 (H3K9ac), thereby potentially affecting gene expression (Fig. 2b ,c and uncropped blots in Supplementary Fig. 12 ). Notably, the expression of two rate-limiting enzymes engaging fatty acid synthesis and cholesterol biogenesis, ATP citrate lyase (ACLY) 29, 30 and squalene epoxidase (SQLE) 31, 32 , was notably low in both Pten pc−/− ; Pdha1 pc-/Y tumors and shPDHA1 human prostate cancer cell lines at both the protein and gene levels ( Fig. 2b-f ).
Downregulation of ACLY in these cells was not associated with the upregulation of acyl CoA synthetase short-chain family member 2 (ACSS2) 33, 34 (Fig. 2d,e ). Genes that divert TCA-cycle and glutamine intermediates into lipid-metabolic pathways 22, 35, 36 were also downregulated by PDHA1 inactivation in both mouse and human prostate tumor cells ( Supplementary Fig. 5d-f ). Importantly, acetate supplementation 30 in the culture medium of 22Rv1 and PC3 cells infected with shPDHA1 restored global levels of H3K9ac, SQLE and ACLY (Fig. 2c ). Chromatin immunoprecipitation (ChIP) analysis demonstrated that H3K9ac and the binding of SREBF1 at the ACLY and SQLE promoters decreased in response to PDHA1 knockdown in human prostate cancer cells, and these effects were restored by acetate supplementation ( Supplementary Fig. 5h ,i and Fig. 2g,h) . Acetate supplementation restored cell growth in both Pten −/− ; Pdha1 -/Y MEFs and shPDHA1 22Rv1 and PC3 cells ( Fig. 2i-k) . Notably, we did not detect any changes in H3K9ac at the promoters of the cell-cycle regulators E2F transcription factor 1 (E2F1) and cyclin D1 (CCND1), thus demonstrating the specificity of the epigenetic regulation of PDC in cancer cells ( Supplementary Fig. 5j,k) . Interestingly, ACLY overexpression in prostate cell lines infected with shPDHA1 rescued the growth arrest induced by loss of PDHA1 only in cells supplemented with citrate ( Supplementary Fig. 5l -n and uncropped blots in Supplementary Fig. 14) , in agreement with previously reported data 30 . 
Fig. 4 | Nuclear PDC regulates the expression of lipid-biosynthesis genes independently of mitochondrial PDC. a, Western blot analysis of the indicated proteins in nuclear and cytoplasmic fractions of shPDHA1 22Rv1 cells infected with NES-PDHA1 and NLS-PDHA1 alone or in combination.
Uncropped images are in Supplementary Fig. 13 (n = 3 independent cell cultures). EV, empty vector. b, Western blot analysis of the indicated proteins in shPDHA1 22Rv1 cells infected with NES-PDHA1 and NLS-PDHA1 alone or in combination (full panel in Supplementary Fig. 5b ). Uncropped images are in Supplementary Fig. 13 Supplementary Fig. 7d ). Error bars, s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. P values were determined by ANOVA with Bonferroni correction, unless otherwise noted.
We next performed a direct measurement of lipid species in mouse prostate tumors and human prostate cancer cell lines depleted of PDHA1. Notably, most lipid species, including cholesterol esters were lower in Pten pc−/− ; Pdha1 pc-/Y tumors than in Pten pc−/− tumors and in shPDHA1 22Rv1 and PC3 cells than in control cells ( Supplementary Fig. 6 , Supplementary Tables 8-11 and Supplementary Note). 14 C tracking experiments demonstrated that glucose and glutamine incorporation into lipids and cholesterol ( Supplementary Fig. 7a-e and Supplementary Note) were strongly affected in in shPDHA1 22Rv1 and PC3 cells compared with controls, whereas glucose and glutamine incorporation into proteins remained unchanged ( Supplementary Fig. 7f,g and Supplementary Note). PDHA1 knockdown did not affect glucose uptake but induced a slight increase in glutamine uptake ( Supplementary  Fig. 7h,i and Supplementary Note). In agreement with these findings, lipid droplets, a known indicator of lipid production 5,37 , were Supplementary Fig. 13 (n = 6 independent tumor samples). Error bars, s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. P values were determined by ANOVA with Bonferroni correction, unless otherwise noted. markedly more scarce in both mouse and human xenograft tumors after PDHA1 inactivation (Fig. 3a-d and Supplementary Fig. 7j-o) . To assess whether lipid metabolism was affected by PDHA1 inactivation, we cultured shPDHA1 22Rv1 and PC3 cells in the presence or absence of fatty acids, and we found that fatty acids fully rescued the growth arrest induced by the PDHA1 knockdown. This observation was associated with the restoration of lipid droplets in the same cells (Fig. 3e,f and Supplementary Note). Rescue of proliferation by fatty acid supplementation occurred independently through H3K9 acetylation and reactivation of the expression of ACLY and SQLE ( Supplementary Fig. 7p and uncropped blots in Supplementary  Fig. 15 ). These data suggested that fatty acids were directly incorporated into lipids. Collectively, our results demonstrated that PDC activity is required for the proliferation of mouse and human prostate tumor cells and that inactivation of PDC drives tumor growth inhibition by affecting H3K9 acetylation and the expression of genes controlling lipid metabolism.
Nuclear PDC regulates expression of lipid-biosynthesis genes independently of mitochondrial PDC. Cellular compartmentalization allows cells to carry out different metabolic reactions simultaneously, and pathological protein compartmentalization is associated with cancer 38 . We therefore investigated the roles of nuclear and cytosolic PDC in prostate cancer, by expressing nuclear export signal (NES)-and/or nuclear localization signal (NLS)-fused PDHA1 vectors in prostate cancer cell lines previously infected with shPDHA1 or left uninfected ( Fig. 4a and uncropped blots in Supplementary Figs. 8a and 13 ). NES-PDHA1 and NLS-PDHA1 constructs were engineered as shPDHA1-resistant vectors. Expression of these vectors in 22Rv1 cells did not affect SREBF1 maturation or nuclear translocation ( Supplementary Fig. 8a ). Restoration of NLS-PDHA1 in shPDHA1 cells restored H3K9ac and the expression of fatty-acid-synthesis genes ( Fig. 4b-d , full panel in Supplementary Fig. 8b and uncropped blots in Supplementary  Figs. 13 and 15 ) but did not rescue citrate levels, lipid content or cell growth both in vitro and in vivo (Fig. 4e-h and Supplementary  Fig. 8c-g) . In contrast, overexpression of both NES-PDHA1 and NLS-PDHA1 restored lipid-synthesis-gene expression, citrate levels, lipid content and cell growth (Fig. 4b-h and Supplementary  Fig. 8b-g) . Interestingly, the selective ACLY inhibitor SB-204990 partially decreased H3K9ac levels in prostate cancer cells with high PDC activity but did not further increase the growth arrest in prostate cancer cells infected with a shPDHA1 ( Supplementary Fig. 8h -j and uncropped blots in Supplementary Fig. 15 ). These data demonstrated that PDC directly contributes to H3K9 acetylation, but not by ACLY 30 . These experiments show that nuclear PDC regulates the expression of lipid-synthesis genes in an autonomous manner, and both nuclear and cytosolic PDHA1 are needed for the proliferation of prostate cancer cells.
Nuclear PDC regulates fatty acid synthesis in the presence of mitochondrial citrate. In agreement with these findings, we showed that overexpression of NLS-PDHA1 rescued growth arrest and lipid synthesis in cells cultured in the presence of citrate (Fig. 5a,b and full panel in Supplementary Fig. 9a ). To validate these findings by using an additional system, we overexpressed PDK1 in prostate cancer cells. Previous evidence has demonstrated that PDK1 overexpression suppresses mitochondrial metabolism, thus decreasing the intracellular levels of citrate without halting the nuclear function of PDC 23, [39] [40] [41] . In line with this evidence, overexpression of PDK did not promote phosphorylation of nuclear PDHA1 ( Supplementary Fig. 9b and uncropped blots in Supplementary Fig. 15 ). Overexpression of PDK1 in 22Rv1 cells decreased citrate levels and slightly suppressed cancer cell proliferation both in vitro and in vivo (Fig. 5c-e and Supplementary  Fig. 8c-e ); however, it did not decrease histone acetylation and expression of fatty-acid-synthesis genes ( Fig. 5f ; uncropped blots in Supplementary Fig. 13 and Supplementary Fig. 9b ). In contrast, concomitant inactivation of PDHA1 and overexpression of PDK1 decreased citrate levels, histone acetylation and lipid content, thereby suppressing tumorigenesis to a greater extent than that in cells infected with PDK1 alone (Fig. 5c-f and Supplementary  Fig. 9c-e ). Together, these results demonstrated that both mitochondrial and nuclear PDC is required for prostate tumor growth.
Pharmacological inhibition of PDHA1 arrests mouse and human prostate tumors. Given that prostate cancer relies on PDC for proliferation, we assessed whether pharmacological inhibition of PDHA1 could also block tumorigenesis in Pten pc−/− tumors and human xenograft models of prostate cancer. Reasoning that a compound affecting both the mitochondrial and nuclear function of PDC might be effective in blocking prostate cancer, we took advantage of 3-fluoropyruvate (3-FP), a competitive inhibitor of PDHA1 (refs [42] [43] [44] [45] ). Computer simulations indicated that 3-FP and pyruvate bind PDHA1 with similar affinity ( Supplementary Fig. 10a,b and Supplementary Note). To assess the specificity of 3-FP for PDC, cell lysates treated with 3-FP were incubated in the presence or absence of pyruvate. Treatment with 3-FP decreased the PDC activity, and this effect was reversed in a dose-dependent manner by addition of pyruvate to the reaction buffer ( Supplementary Fig. 10c ). Intraperitoneal injection of 3-FP in Pten pc−/− mice inhibited PDC activity in vivo without causing systemic toxicity and induced a strong decrease in tumor cell proliferation, as demonstrated by the smaller tumor size and the lower tumor invasiveness and Ki-67 staining ( Supplementary Fig. 10d-j) . Importantly, 3-FP inhibited PDC in both the nucleus and the cytosol in prostate tumor cells and decreased H3K9ac, ACLY and SQLE levels in vivo at both the protein and mRNA levels ( Supplementary Fig. 10k -m and uncropped blots in Supplementary Fig. 15 ). Metabolomic analysis via liquid chromatography-tandem mass spectrometry (LC-MS/MS) 46 confirmed that 3-FP strongly affected pyruvate metabolism and the TCA cycle ( Supplementary Fig. 11a ). Finally, lipid-droplet staining showed decreases in the number, size and staining intensity of lipid bodies in Pten pc−/− tumors treated with 3-FP ( Supplementary  Fig. 11b-e ). 3-FP treatment blocked the proliferation of different human prostate cancer cells, and this effect was associated with decreased PDC activity ( Supplementary Fig. 11f,g) . Finally, 3-FP treatment decreased the proliferation of different human prostate cancer xenografts (LNCaP, 22Rv1 and PC3), thus promoting longlasting antitumor responses in vivo ( Supplementary Fig. 11h-j) . Together, these data suggest that pharmacological inactivation of PDC hinders prostate cancer progression.
Discussion
Whether PDC promotes or suppresses tumor development is still under debate 19, 22, 23, 39, 40, [47] [48] [49] . A previous report has shown that decreased PDC activity through overexpression of PDK1 in melanoma cells promotes tumor cell proliferation by enhancing glycolysis and reductive carboxylation 19 . In this and other models, activation of PDC by dichloroacetate leads to tumor suppression 19, 47 . Our data reveal a new angle by demonstrating that PDC subunits, including PDHA1 and PDP1, are amplified and overexpressed at both the gene and protein levels and that PDC is active in prostate cancer. In line with this evidence, we demonstrated that inactivation of PDHA1 hinders prostate cancer progression in vivo in both mouse and human prostate cancer models. These findings are in agreement with those from recent studies demonstrating that tumor cells, in vivo, increase glucose oxidation via PDC. PDHA1 inactivation in non-small cell lung cancer (NSCLC) xenografts decreases tumor formation ability, and upregulation of the TCA cycle via PDC has also been observed in poorly perfused tumor areas in patients with NSCLC 9,10,50 . These data, together with our data in prostate cancer, challenge the notion that tumors switch from glucose-derived oxidative metabolism to aerobic glycolysis to support their growth 6 . However, the mechanisms by which tumor cells in vivo become addicted to PDC-mediated mitochondrial metabolism still remain unknown. As suggested by previous studies, this metabolic dependency may be explained by differences in tumor genetic backgrounds, tissue requirements or the composition of the tumor microenvironment 10 . Intriguingly, normal prostate epithelial cells exhibit a 'truncated' TCA cycle, owing to inhibition of aconitase, which is needed for the production and secretion of a high quantity of citrate into the seminal fluid [51] [52] [53] . Therefore, it is not surprising that prostate cancer relies on mitochondrial metabolism more than do other tumor types.
Our results indicate that to support prostate cancer growth, PDC must be functional in both the mitochondria and the nuclei in cancer cells. Mitochondrial PDC function is not sufficient to support lipid biosynthesis in tumor cells, because nuclear PDC regulates the transcription of the enzymes that convert cytosolic citrate into acetyl CoA and fatty acids ( Supplementary Fig. 11k,l) . This compartmentalization allows for the mitochondrial production of citrate in the cytosol and the expression of enzymes required for de novo lipid biosynthesis. Prior studies have demonstrated that prostate cancer also benefits from enhanced glycolytic metabolism. However, these aggressive glycolytic tumor cells retain an active glucose-derived lipid biosynthesis 54 , in line with the results presented herein.
Our findings also have important implications for potential cancer therapy and may pave the way for the targeting of the nuclear function of PDC to eradicate prostate cancer. Future eradication might be achieved as described in this paper by using pyruvate analogs or alternatively by developing small-molecule inhibitors of PDHA1. 
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Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0026-3.
Isotope labeling and stationary profiling. Fresh transgenic mouse tumor tissues were mechanically dissociated, enzymatically digested and filtered to obtain singlecell suspensions as previously described 60 . Single cells were stained with fluorescein isothiocyanate (FITC)-anti-CD34 (560238, BD Biosciences) for stroma cells, FITCanti-Ter119 (557915, BD Biosciences) for erythrocytes, FITC-anti-CD31 (561813, BD Biosciences) for endothelial cells and FITC-anti-CD45 (553079, BD Bioscience) for leukocytes, and were incubated 20 min on ice. All antibodies (BD Biosciences) were used at 1:300; cells were then loaded into an MS column with anti-FITC MicroBeads (130-048-701, Miltenyi Biotec) for MACS separation, and unstained epithelial cells were collected in the negative fraction. For steady-state metabolomic analysis 5 , prostate epithelial cells derived from transgenic mouse tumors were plated to ~80% confluence on 10-cm dishes in biological quadruplicate. Cells were plated in RPMI medium (11875093, Thermo Scientific) supplemented with 10% dialyzed serum, devoid of glucose or glutamine, and containing one of the two 13 C-labeled substrates [U-13 C 6 ]glucose and [U-13 C 5 ]glutamine (CLM-1396-1 and CLM-1822-H-0.25, Cambridge Isotope Labs), whereas the remaining substrates were unlabeled (11 mM glucose and 2 mM glutamine). Fatty acid oxidation studies 20 were conducted with [U- 13 C 16 ]palmitate (CLM-6059-1, Cambridge Isotope Labs) noncovalently bound to fatty acid-free BSA. [U- 13 C 16 ]palmitate-BSA was added to the culture medium at 5% of the final volume (50 mM final concentration) with 1 mM carnitine in medium formulated with delipidated FBS (12676011, Thermo Scientific). Additionally, fresh medium containing 13 C-labeled substrates was exchanged 2 h before metabolite extraction for steady-state analyses. Because primary epithelial cells isolated from mouse prostate tissue do not attach and are thus unsuitable for long-term culture, we labeled these epithelial cells for 6 h, and we observed no differences compared with the results of labeling for 24 h. After 6 h of incubation with labeled substrates, metabolite extraction of the medium was performed by addition of 1 ml cold (-80 °C) 80% methanol (34966-1 L and 14263-1 L, Sigma), incubation at − 80 °C for 30 min and centrifugation at 10,000g for 10 min at 4 °C. The resultant supernatant was lyophilized in a SpeedVac and stored at − 80 °C until analysis. Dried metabolite pellets were resuspended in 20 μ l LC-MS-grade water, and 5 μ l was injected onto a Prominence UFLC and separated with a 4.6-mm i.d. × 100 mm Amide XBridge HILIC column at 360 μ l/min starting from 85% buffer B (100% ACN) to 0% B over 16 min. Buffer A consisted of 20 mM NH 4 OH and 20 mM CH 3 COONH 4 , pH 9.0, in 95:5 water/ACN.287. Selected reaction monitoring (SRM) transitions were captured through positive/negative polarity switching by targeted LC-MS/MS with a 5500 QTRAP hybrid triplequadrupole mass spectrometer. For metabolomics, the quantity of the metabolite fraction analyzed was adjusted to the corresponding protein concentration from a sample processed in parallel. The analysis was performed for each of the three substrates on three independent tumors in biological triplicate.
Lipidomics analysis of transgenic-mouse prostate tumors. Approximately 5 mg of solid tissue was snap frozen in liquid nitrogen (− 196 °C) as close to the time of resection as possible. Chloroform/methanol (2:1) was added to a final volume 20 times the volume of the biological sample (100 µ l in 2 ml of solvent mixture) in a 12-ml glass vial. The mixture was agitated for 30 min in an orbital shaker at room temperature; then 0.2 volumes of water (e.g., 400 µ l for 2 ml) was added, and the mixture was vortexed for 1 min. The mixture was allowed to rest for 10 min and was then centrifuged at low speed (1,000g) to separate it into three phases. The upper aqueous phase was kept (optionally) to analyze small organic polar molecules. The middle layer contained protein, DNA and large polE molecules. The lower phase containing nonpolar lipids was collected and evaporated under vacuum with a SpeedVac or under a nitrogen stream. 10 µ l of sample was injected for LC-MS/MS with a hybrid QExactive Plus Orbitrap mass spectrometer in DDA mode with positive/negative ion-polarity switching (top eight in both modes). With a 100-mm × 2.0-mm C18 column at 260 µ l/min with a 1100 quaternary HPLC, lipids were eluted over 20 min from 32% buffer B (90% IPA, 10% can, 10 mM NH 4 HCO 2 and 0.1% FA) to 97% B. Buffer A consisted of 59.9% can, 40% water, 10 mM NH 4 HCO 2 and 0.1% FA. Lipid molecules were identified and quantified with LipidSearch 4.1.9 software 61 .
Statistics. For each independent in vitro experiment, at least three technical replicates were used (exceptions: in western blot analysis, technical replicates were used; in targeted metabolomics, three technical replicates were used). For datamining analysis, ANOVA tests were used for multicomponent comparisons, and Student's t tests were used for paired comparisons. In the in vitro experiments, data groups were assessed for normal distribution, and Student's t test was applied for paired comparisons. Data represent mean ± s.e.m. of pooled experiments unless otherwise stated. n values represent the numbers of experimental samples, and all the experiments were repeated at least three times. For in vivo experiments, because equal variance could not be assumed, a nonparametric Mann-Whitney test was used. The confidence level used for all the statistical analyses was 0.95 (α = 0.05). Two-tailed statistical analysis was applied for experimental designs without predicted results, and one-tailed statistical analysis was applied for validation experiments (*P < 0.05; **P < 0.01; ***P < 0.001).
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. The mouse gene expression datasets are available at NCBI's Gene Expression Omnibus database under accession number GSE74245. For cellular, molecular and metabolic assays, the lipidomic analysis on prostate cancer cell lines, fatty acid rescue assays and computer simulations of 3-FP and PDC docking, methods are available in the Supplementary Note. nature research | life sciences reporting summary June 2017
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